Programmed Death Receptor-1-directed Antibody Interactions

Name
Programmed Death Receptor-1-directed Antibody Interactions
Accession Number
DBCAT004275
Description

Not Available

Drugs
DrugDrug Description
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
Drugs & Drug Targets
DrugTargetType
PembrolizumabProgrammed cell death protein 1target
NivolumabProgrammed cell death protein 1target
AtezolizumabProgrammed cell death 1 ligand 1target
DostarlimabProgrammed cell death protein 1target